Headlines Expert Newsletters Covid-19 Specialties Trending Feeds Videos

Sophia Kamran, MD, discusses future roles that radiation oncology will play in combination with resection and targeted therapy in urothelial...

In the first installment of the series, Allison Betof Warner, MD, PhD, reviews the mechanistic rationale behind tumor-infiltrating lymphocytes and considers where these experimental...

The phase 3 RATIONALE 301 trial of tislelizumab in patients with unresectable hepatocellular carcinoma has met its primary end point of non-inferior overall...

The combination of paxalisib and radiotherapy exhibited complete or partial responses in all patients with brain metastases, according to interim data from an ongoing...

  • 1558092034656948224 Profile photo of Madelyn

    Paxalisib in combination with radiotherapy demonstrated complete or partial responses in all patients with brain metastases, according to interim data from an ongoing phase I clinical trial. #brainmets #cancer https://t.co/fRzX9VS55n - view on twitter

Mashup Score:5

Targeted Oncology

Intensive Induction Therapy In AML - 1 week

Mashup Score:5

Hetty Carraway, MD, describes the criteria used to determine if a patient with newly-diagnosed acute myeloid leukemia is suitable for intensive induction...

Ghassan K. Abou-Alfa, MD,discusses the phase 2 study of tislelizumab in patients with unresectable hepatocellular...

An accelerated approval by the FDA for capmatinib has be converted to a regular approval based on new data from adults patients with metastatic...

  • 1557836428347858948 Profile photo of Madelyn

    BREAKING: Regular #FDA approval has been granted to #capmatinib for adult patients with metastatic non–small cell lung cancer whose tumors have a mutation leading to MET exon 14 skipping, as detected by an FDA-approved test. #nsclc #lcsm https://t.co/1E9JPGW3s6 - view on twitter

Based on findings from the interim phase 1 portion of a trial examining ART4215 in combination with talazoparib in BRCA deficient breast cancer, a...

  • 1557795210440032256 Profile photo of Madelyn

    BREAKING: The #FDA has accepted a new drug application for the selective estrogen receptor degrader, elacestrant, and granted it priority review for the treatment of ESR1-positive, HER2-negative advanced or metastatic breast cancer. #bcsm https://t.co/dEiiMnKXU7 - view on twitter

Oncologists share some final thoughts on lutetium-PSMA-617 and novel agents to look out for in prostate cancer...

Tepotinib achieved robust efficacy in patients with non–small cell lung cancer harboring MET exon 14 skipping alterations, according to a primary analysis of cohort...

  • 1556732492878675969 Profile photo of Madelyn

    Tepotinib achieved robust efficacy in patients with non–small cell lung cancer harboring MET exon 14 skipping alterations, according to a primary analysis of cohort C of the phase 2 VISION trial. #WCLC22 #lcsm https://t.co/Bh5dAkIoiP - view on twitter